Ihab Soliman
Child & Adolescent Psychiatry · Corona del Mar, CANPI 1851594212
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $75,135 of the $93,423 with a category attached, or 80.4%. Supernus Pharmaceuticals, Inc. accounts for 67.0% of it on its own, with 24 other manufacturers making up the rest. Among child & adolescent psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 629 payments — averaging $148.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$63K
- Ironshore Pharmaceuticals Inc.$23K
- Tris Pharma Inc$1K
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$746
- plus $3K from 19 others
What the payments were for
- Consulting fees$1,2801%
- Speaking & faculty fees$75,13580%
- Travel & lodging$5,9126%
- Food & beverage$11,04212%
- Education$540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 133 | $62,623 |
| Ironshore Pharmaceuticals Inc. | 106 | $23,337 |
| Tris Pharma Inc | 80 | $1,452 |
| AbbVie(2 entities) | 81 | $1,341 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 55 | $1,039 |
| Alkermes, Inc. | 35 | $746 |
| Corium, LLC | 31 | $738 |
| Bausch Health US, LLC | 18 | $343 |
| Sunovion Pharmaceuticals Inc. | 16 | $271 |
| Otsuka America Pharmaceutical, Inc. | 12 | $269 |
| Lundbeck LLC | 10 | $213 |
| E.r. Squibb & Sons, L.L.C. | 7 | $173 |
| Neos Therapeutics, LP | 8 | $156 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $116 |
| Vertical Pharmaceuticals, LLC | 5 | $109 |
| Vanda Pharmaceuticals Inc. | 5 | $102 |
| Arbor Pharmaceuticals, Inc. | 3 | $71 |
| Collegium Pharmaceutical, Inc. | 3 | $57 |
| Idorsia Pharmaceuticals US Inc | 3 | $48 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| Almatica Pharma LLC | 2 | $46 |
| Adlon Therapeutics L.p. | 2 | $46 |
| Johnson & Johnson | 2 | $44 |
| Neuronetics, Inc. | 1 | $20 |
| Dentsply Sirona Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$60,726
- JORNAY PM$18,424
- Jornay PM 20mg capsules (Bottle of 100)$3,520
- LYBALVI$488
How this compares
$93,423 in reported general payments places this provider in the 95th percentile of 434 child & adolescent psychiatry providers in California.
See all child & adolescent psychiatry providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 14 | $20,174 |
| TrintellixVortioxetine Hydrobromide | 35 | $17,039 |
| VraylarCariprazine Hcl | 11 | $15,510 |
| VyvanseLisdexamfetamine Dimesylate | 38 | $14,256 |
| Adzenys Xr-OdtAmphetamine | 13 | $6,888 |
| Dyanavel XrAmphetamine | 18 | $6,855 |
| Lisdexamfetamine Dimesylate | 18 | $2,808 |
| Methylphenidate ErMethylphenidate Hcl | 24 | $2,714 |
| Oxazepam | 27 | $1,851 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 43 | $1,662 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 45 | $1,231 |
| Bupropion XlBupropion Hcl | 60 | $1,173 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 25 | $1,156 |
| Divalproex Sodium ErDivalproex Sodium | 12 | $1,052 |
| Dextroamphetamine Sulfate | 19 | $918 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $116 | $31,29573 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $269 | $20,17414 claims |
| AbbVieVraylar | $1,341 | $15,51011 claims |
| Neos Therapeutics, LPAdzenys Xr-Odt | $156 | $6,88813 claims |
| Tris Pharma IncDyanavel Xr | $1,452 | $6,85518 claims |
| Almatica Pharma LLCSertraline Hcl | $46 | $35146 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 434 child & adolescent psychiatry providers in California.
Other child & adolescent psychiatry in Corona del Mar
- Kevin CoxOjai$2.9M
- Sukhjit BrarFresno$283K
- Manpreet SinghSacramento$104K
- Syed NaqviLos Angeles$69K
- Ellen HeynemanSan Diego$62K
- Mark McDonaldLos Angeles$31K
- James HartmanDanville$21K
- Mohsin KhaliqueSan Ramon$20K
- Mansoor ZuberiWalnut Creek$16K
- Michael McManusSan Diego$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.